Theravance-GSK's Relvar is backed for approval in EU for asthma, COPD

09/20/2013 | Reuters

The European Medicines Agency endorsed the approval of GlaxoSmithKline and Theravance's Relvar as a treatment for asthma and chronic obstructive pulmonary disease. The inhaled drug, marketed as Breo in the U.S., is a combination of corticosteroid and a long-acting beta-agonist. A final decision is expected in the next quarter.

View Full Article in:

Reuters

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Operating Officer
Health Plan of San Joaquin
French Camp , CA
Chief Medical Officer, Texas Children's Health Plan
Cejka Executive Search for Texas Children's Health Plan
Houston, TX
Chief Information Officer
Meridian Health Plan
Detroit, MI
Actuary
NTA Life
Addison, TX
Vice President - Government Products
Health Alliance Plan
Detroit, MI